No / Triple negative breast cancers (TNBC) are clinically heterogeneous, an aggressive subtype with poor diagnosis and strong resistance to therapy. There is a need to identify novel robust biomarkers with high specificity for early detection and therapeutic intervention. Microarray gene expression-based studies have offered significant advances in molecular classification and identification of diagnostic/prognostic signatures, however sample scarcity and cohort heterogeneity remains area of concern. In this study, we performed integrated analysis on independent microarray big data studies and identified a robust 880-gene signature for TNBC diagnosis. We further identified 16-gene (OGN, ESR1, GPC3, LHFP, AGR3, LPAR1, LRRC17, TCEAL1, CIRBP, NTN4, TUBA1C, TMSB10, RPL27, RPS3A, RPS18, and NOSTRIN) that are associated to TNBC tissues. The 880-gene signature achieved excellent classification accuracy ratio on each independent expression data sets with overall average of 99.06%, is an indication of its diagnostic power. Gene ontology enrichment analysis of 880-gene signature shows that cell-cycle pathways/processes are important clinical targets for triple negative breast cancer. Further verification of 880-gene signature could provide additive knowledge for better understanding and future direction of triple negative breast cancer research.
| Identifer | oai:union.ndltd.org:BRADFORD/oai:bradscholars.brad.ac.uk:10454/9254 |
| Date | January 2015 |
| Creators | Zaka, Masood-Ul-Hassan, Peng, Yonghong, Sutton, Chris W. |
| Source Sets | Bradford Scholars |
| Detected Language | English |
| Type | Conference Paper, No full-text available in the repository |
Page generated in 0.0018 seconds